MEHOW INNOVATIVE LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 CNY | -1.13% |
|
-2.39% | -33.42% |
| 05-10 | Mehow Innovative Ltd. Approves Cash Dividend for 2023 | CI |
| 04-17 | MeHow Innovative Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm trades with high earnings multiples: 25.1 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -33.42% | 1.38B | - | ||
| +12.15% | 227B | B | ||
| +14.90% | 197B | B- | ||
| +18.22% | 141B | B- | ||
| +29.15% | 110B | A- | ||
| +0.53% | 64.15B | A- | ||
| +16.92% | 53.72B | B+ | ||
| +6.33% | 51.75B | B+ | ||
| +10.93% | 45.2B | A | ||
| +5.87% | 37.37B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 301363 Stock
- Ratings Mehow Innovative Ltd.
